The European Gastric and Esophageal Cancer Market Expands Its Therapy Options in Q4 2025 

MSD consistently positioned Keytruda as a leading first-line option in advanced gastrointestinal cancers.

LEO Pharma featured Loqtorzi as an effective novel first-line option for advanced ESCC with significant improvements in PFS and OS regardless of PD-L1 expression.

BMS advertised Opdivo’s five-year survival benefit when used in combination with chemotherapy for HER2-negative patients with PD-L1 CPS ≥ 5.

BeiGene presented Tevimbra as a promising and effective PD-1 inhibitor for esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancers.

Astellas positioned Vyloy as an effective, targeted first-line therapy for patients with HER2-negative, Claudin 18.2–positive metastatic gastric and AEG adenocarcinoma.